Early-Line Infigratinib for Patients with FGFR3-Altered Metastatic Urothelial Carcinoma – Expert Commentary
The standard-of-care first-line systemic therapy for metastatic urothelial cancer (mUC) remains platinum-based chemotherapy. Post-platinum options included immune checkpoint inhibitors, fibroblast growth factor receptor (FGFR) inhibitors in patients with FGFR2 or FGFR3 genomic alterations, or antibody-drug conjugates. However, the best sequence of these systemic therapies is unknown. Furthermore, it is unclear if patients with FGFR2 or […]